Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase Ib/II Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Summary

The purpose of this phase I/II trial is to evaluate the safety and feasibility of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy.

General Information

NCT#: NCT05102721
Study ID: SGIP21027
Trial Phase: Phase I/II

Trial Sponsor: University of Rochester, Vaccinex
Therapies Used in This Trial: Pepinemab, Avelumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search